ReviewBlood2012
Does size matter in platelet production?
Review in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 88 citations in OpenAlex.
- [The application of thrombopoietin receptor agonists in the treatment of non-muscle myosin heavy chain 9-related disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Review
- Molecular diagnosis of inherited platelet disorders: a tale of two realities - advanced vs. resource-limited setting.Thrombosis journal · 2025Review
- Isolation Techniques of Micro/Nano-Scaled Species for Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Mean platelet volume: A versatile biomarker in clinical diagnostics and prognostics.Bioinformation · 2025Article
- Immature platelet fraction in cardiovascular diagnostics and antiplatelet therapy monitoring.Cardiology journal · 2023Review
- The high platelet counts as predictor for early foetal demise.Annals of medicine · 2021Article
- Cytoskeletal-based mechanisms differently regulateHaematologica · 2021Article
- Elucidating a false-negativeCold Spring Harbor molecular case studies · 2019Article
- The cytoskeletal crosslinking protein MACF1 is dispensable for thrombus formation and hemostasis.Scientific reports · 2019Article
- Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer.Nature medicine · 2019Article
- Prognostic value of rising mean platelet volume during hospitalization in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.BMC cardiovascular disorders · 2018Article
- Variants in exons 5 and 6 of ACTB cause syndromic thrombocytopenia.Nature communications · 2018Article
- A characteristic flow cytometric pattern with broad forward scatter and narrowed side scatter helps diagnose immune thrombocytopenia (ITP).International journal of hematology · 2018Article
- Review
- Species-Specific Involvement of Integrin αIIbβ3 in a Monoclonal Antibody CH12 Triggers Off-Target Thrombocytopenia in Cynomolgus Monkeys.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Biology of Platelet Purinergic Receptors and Implications for Platelet Heterogeneity.Frontiers in pharmacology · 2018Review
- Towards the Manufacture of Megakaryocytes and Platelets for Clinical Application.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2017Review
- Normal platelet function.Cancer metastasis reviews · 2017Review
- Platelet Shape Changes and Cytoskeleton Dynamics as Novel Therapeutic Targets for Anti-Thrombotic Drugs.Biomolecules & therapeutics · 2017Review
- Loss of the Arp2/3 complex component ARPC1B causes platelet abnormalities and predisposes to inflammatory disease.Nature communications · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Platelet (PLT) production represents the final stage of megakaryocyte (MK) development. During differentiation, bone marrow MKs extend and release long, branched proPLTs into sinusoidal blood vessels, which undergo repeated abscissions to yield circulating PLTs. Circular-prePLTs are dynamic intermediate structures in this sequence that have the capacity to reversibly convert into barbell-proPLTs and may be related to "young PLTs" and "large PLTs" of both inherited and acquired macrothrombocytopenias. Conversion is regulated by the diameter and thickness of the peripheral microtubule coil, and PLTs are capable of enlarging in culture to generate barbell-proPLTs that divide to yield 2 smaller PLT products. Because PLT number and size are inversely proportional, this raises the question: do macrothrombocytopenias represent a failure in the intermediate stages of PLT production? This review aims to bring together and contextualize our current understanding of terminal PLT production against the backdrop of human macrothrombocytopenias to establish how "large PLTs" observed in both conditions are similar, how they are different, and what they can teach us about PLT formation. A better understanding of the cytoskeletal mechanisms that regulate PLT formation and determine PLT size offers the promise of improved therapies for clinical disorders of PLT production and an important source of PLTs for infusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.